Citing increasing evidence of substantial abuse and diversion of tramadol, the Drug Enforcement Administration (DEA) proposes oversight of tramadol as a Schedule IV substance. The DEA seeks comments on the proposed scheduling of tramadol through January 3, 2014.
Recognizing the value of tramadol in veterinary medicine, our volunteer governance groups led by the Council on Biologic and Therapeutic Agents, Clinical Practitioners Advisory Committee, and Council on Veterinary Service are assessing the DEA’s proposal. In previous correspondence on opioid issues, in line with our mission, AVMA has recognized public health concerns regarding abuse/misuse, while also underscoring to the federal government the importance of such products in veterinary practice. In line with previous federal findings, we have also underscored to federal agencies how little diversion is associated with the veterinary medical profession.
To read more about current issues related to controlled substances, see our suggestions on compliance with DEA’s rules, and information on AVMA’s advocacy activities on DEA issues (including our strong advocacy on Capitol Hill for the Veterinary Medicine Mobility Act).